Imunoglukan Overview

  • Year Founded
  • 2000

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 50

Employees

  • Latest Deal Type
  • M&A

  • Financing Rounds
  • 2

Imunoglukan General Information

Description

Manufacturer of immunity-focused dietary supplements intended to boost the immunity of consumers. The company engages in research, development and sale of immunity medicines and dietary supplements, it manufactures imunoglukan which is a highly purified natural substance, the complex of biologically active polysaccharides obtained through the isolation from Pleurotus ostreatus.

Contact Information

Website
www.imunoglukan.com
Ownership Status
Acquired/Merged
Financing Status
Formerly PE-Backed
Corporate Office
  • Nove Zahrady I c. 13/A
  • Bratislava, 821 05
  • Slovakia
Primary Industry
Other Consumer Non-Durables
Vertical(s)
Manufacturing
Corporate Office
  • Nove Zahrady I c. 13/A
  • Bratislava, 821 05
  • Slovakia

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Imunoglukan Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Imunoglukan‘s full profile, request access.

Request a free trial

Imunoglukan Patents

  • 15

    Total Documents Applications and Grants

  • Total Patents Families

  • 3

    Granted

  • 3

    Pending

  • Expiring in next 12 mo

Imunoglukan Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20230045997-A1 Beta-glucan for use in modulation of an immune response in a remission Pending 29-Jan-2020
EP-3858362-A1 Beta-glucan for use in enhancement of anti-tumor immunity in remission Pending 29-Jan-2020
EP-4096685-A1 Beta-glucan for use in modulation of an immune response in a remission Pending 29-Jan-2020
DE-602005010392-D1 Method for the preparation of pilzglucan hydrogels with antibacterial and immunostimulating effect, and their use Inactive 14-Jan-2004
ES-2315836-T3 Method of preparation of a micotic glucan hydrogel that has bacterial and immuno stimulating activity, and use of it. Inactive 14-Jan-2004 A61K9/0014
To view Imunoglukan’s complete patent history, request access »

Imunoglukan Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Imunoglukan Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Imunoglukan‘s full profile, request access.

Request a free trial

Imunoglukan FAQs

  • When was Imunoglukan founded?

    Imunoglukan was founded in 2000.

  • Where is Imunoglukan headquartered?

    Imunoglukan is headquartered in Bratislava, Slovakia.

  • What is the size of Imunoglukan?

    Imunoglukan has 50 total employees.

  • What industry is Imunoglukan in?

    Imunoglukan’s primary industry is Other Consumer Non-Durables.

  • Is Imunoglukan a private or public company?

    Imunoglukan is a Private company.

  • What is Imunoglukan’s current revenue?

    The current revenue for Imunoglukan is .

  • Who are Imunoglukan’s investors?

    Hartenberg Holding has invested in Imunoglukan.

  • When was Imunoglukan acquired?

    Imunoglukan was acquired on 01-Aug-2024.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »